April 15, 2017

CATAWBA RESEARCH CONCLUDES ANOTHER ROSACEA CLINICAL TRIAL

Rosacea Clinical Trial Spotlight:

Catawba Research is pleased to announce another achievement for a recently completed rosacea clinical trial. In this trial, Catawba enrolled more than 1000 rosacea subjects in 22 weeks from 33 sites.

The time line for the entire project including investigational product at the site to delivery of final clinical study report was 9 months.  Catawba Research continues its excellent 100% track record in successfully completing clinical trials on time without a single change order.

Catawba Research is proud of yet another rapid study completion and committed to achieving aggressive timelines for our clients.

Get in touch with us for additional information.

Won’t you get hip to this kindly tip, get your kicks on Route 505(b)(2). What is that?Route 505(b)(2) vs. 505(j)Altasciences Acquires WCCT Global“ This acquisition is an integral part of Altasciences’ strategic growth plan to provide a comprehensive, fully integrated early phase drug development solution to address the ever-changing outsourcing challenges of biopAn Overview of GDUFAThe Office of Generic Drugs (OGD) reports directly to the Director of the Center for Drug Evaluation and Research (CDER). The OGD’s mission is to ensure safe, effective, and affordable medicines for the American public.Catawba Research Concludes Another Rosacea Clinical TrialCatawba Research is pleased to announce another achievement for a recently completed rosacea clinical trial. In this trial, Catawba enrolled more than 1000 rosacea subjects in 22 weeks from 33 sites .Catawba Research Achieves Acne First-to-FileThe team at Catawba Research has recently completed a first-to-file submission for acne clinical trial . In this study, Catawba enrolled a staggering 1125 acne vulgaris subjects in 8 weeks from 12 sites .Catawba Research Adds Tinea Pedis Video to Training LibraryTo learn more about our training program or see some our videos, contact us !